Estimating hepatitis C prevalence in the United States, 2017-2020
- PMID: 38739849
- PMCID: PMC11557732
- DOI: 10.1097/HEP.0000000000000927
Estimating hepatitis C prevalence in the United States, 2017-2020
Abstract
Background and aims: The National Health and Nutrition Examination Survey (NHANES) underestimates the true prevalence of HCV infection. By accounting for populations inadequately represented in NHANES, we created 2 models to estimate the national hepatitis C prevalence among US adults during 2017-2020.
Approach and results: The first approach (NHANES+) replicated previous methodology by supplementing hepatitis C prevalence estimates among the US noninstitutionalized civilian population with a literature review and meta-analysis of hepatitis C prevalence among populations not included in the NHANES sampling frame. In the second approach (persons who injected drugs [PWID] adjustment), we developed a model to account for the underrepresentation of PWID in NHANES by incorporating the estimated number of adult PWID in the United States and applying PWID-specific hepatitis C prevalence estimates. Using the NHANES+ model, we estimated HCV RNA prevalence of 1.0% (95% CI: 0.5%-1.4%) among US adults in 2017-2020, corresponding to 2,463,700 (95% CI: 1,321,700-3,629,400) current HCV infections. Using the PWID adjustment model, we estimated HCV RNA prevalence of 1.6% (95% CI: 0.9%-2.2%), corresponding to 4,043,200 (95% CI: 2,401,800-5,607,100) current HCV infections.
Conclusions: Despite years of an effective cure, the estimated prevalence of hepatitis C in 2017-2020 remains unchanged from 2013 to 2016 when using a comparable methodology. When accounting for increased injection drug use, the estimated prevalence of hepatitis C is substantially higher than previously reported. National action is urgently needed to expand testing, increase access to treatment, and improve surveillance, especially among medically underserved populations, to support hepatitis C elimination goals.
Copyright © 2024 American Association for the Study of Liver Diseases.
Conflict of interest statement
Heather Bradley and Eric W.Hall consults for Merck. Patrick Sullivan consults and received grants from Merck. He is on the speakers’ bureau and received grants from Gilead and received grants from Viiv. The remaining authors have no conflicts to report.
Figures
References
-
- Centers for Disease Control and Prevention (CDC). Viral Hepatitis Surveillance Report – United States, 2021. Accessed August 10, 2023. https://www.cdc.gov/hepatitis/statistics/2021surveillance/index.htm
-
- US Department of Health & Human Services. Viral Hepatitis National Strategic Plan for the United States: A Roadmap to Elimination (2021–2025). Washington, DC, USA: US Department of Health and Human Services; 2020.
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical